Polyoxidonium - compositium pro formum medicinalium et vaccinum
Polyoxidonium - compositium pro formum medicinalium et vaccinum Uses, Dosage, Side Effects, Food Interaction and all others data.
Polyoxidonium - compositium pro formum medicinalium et vaccinum is under investigation in clinical trial NCT04381377 (Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19).
| Trade Name | Polyoxidonium - compositium pro formum medicinalium et vaccinum |
| Generic | Azoximer bromide |
| Azoximer bromide Other Names | Azoximer bromide, Poly((1-(carboxymethyl)piperazin-1-ium-1,4-diyl bromide)ethylene-co-((piperazin-1,4-diyl 1-oxide)ethylene) |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Russia |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Polyoxidonium - compositium pro formum medicinalium et vaccinum
